234 related articles for article (PubMed ID: 16013987)
1. Miltefosine to treat leishmaniasis.
Berman J
Expert Opin Pharmacother; 2005 Jul; 6(8):1381-8. PubMed ID: 16013987
[TBL] [Abstract][Full Text] [Related]
2. Treatment of leishmaniasis with miltefosine: 2008 status.
Berman JJ
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
[TBL] [Abstract][Full Text] [Related]
3. [Miltefosine: a new remedy for leishmaniasis].
Dorlo TP; Eggelte TA; Beijnen JH; de Vries PJ
Ned Tijdschr Geneeskd; 2006 Dec; 150(49):2697-701. PubMed ID: 17194005
[TBL] [Abstract][Full Text] [Related]
4. Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis.
Fischer C; Voss A; Engel J
Med Microbiol Immunol; 2001 Nov; 190(1-2):85-7. PubMed ID: 11770118
[TBL] [Abstract][Full Text] [Related]
5. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
Croft SL; Engel J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
[TBL] [Abstract][Full Text] [Related]
6. Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations.
Monge-Maillo B; López-Vélez R
Clin Infect Dis; 2015 May; 60(9):1398-404. PubMed ID: 25601455
[TBL] [Abstract][Full Text] [Related]
7. Miltefosine for new world cutaneous leishmaniasis.
Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
[TBL] [Abstract][Full Text] [Related]
8. Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA.
de Vries PJ; van der Meide WF; Godfried MH; Schallig HD; Dinant HJ; Faber WR
Trans R Soc Trop Med Hyg; 2006 Dec; 100(12):1183-6. PubMed ID: 16678871
[TBL] [Abstract][Full Text] [Related]
9. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
[TBL] [Abstract][Full Text] [Related]
10. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent.
Soto J; Toledo J; Gutierrez P; Nicholls RS; Padilla J; Engel J; Fischer C; Voss A; Berman J
Clin Infect Dis; 2001 Oct; 33(7):E57-61. PubMed ID: 11528586
[TBL] [Abstract][Full Text] [Related]
11. Miltefosine for visceral leishmaniasis.
Eibl H
N Engl J Med; 2000 Mar; 342(12):894-5. PubMed ID: 10733376
[No Abstract] [Full Text] [Related]
12. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
[TBL] [Abstract][Full Text] [Related]
13. A case of miltefosine responsive pleomorphic post kala-azar dermal leishmaniasis.
Pal D; Naskar A; Ghosh MK
Braz J Infect Dis; 2013; 17(5):610-2. PubMed ID: 24012431
[No Abstract] [Full Text] [Related]
14. Oral miltefosine treatment in children with visceral leishmaniasis: a brief review.
Palumbo E
Braz J Infect Dis; 2008 Feb; 12(1):2-4. PubMed ID: 18553005
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis.
Sundar S; Singh A; Chakravarty J; Rai M
ScientificWorldJournal; 2015; 2015():414378. PubMed ID: 25685839
[TBL] [Abstract][Full Text] [Related]
16. Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
Ramesh V; Ansari NA; Jain RK; Salotra P
Clin Exp Dermatol; 2008 Jan; 33(1):103-5. PubMed ID: 17979988
[No Abstract] [Full Text] [Related]
17. Oral miltefosine for Indian visceral leishmaniasis.
Sundar S; Jha TK; Thakur CP; Engel J; Sindermann H; Fischer C; Junge K; Bryceson A; Berman J
N Engl J Med; 2002 Nov; 347(22):1739-46. PubMed ID: 12456849
[TBL] [Abstract][Full Text] [Related]
18. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.
Sundar S; Jha TK; Sindermann H; Junge K; Bachmann P; Berman J
Pediatr Infect Dis J; 2003 May; 22(5):434-8. PubMed ID: 12792385
[TBL] [Abstract][Full Text] [Related]
19. [Leishmaniasis--oral treatment with hexadecylphosphocholine].
Bommer W; Eibl HJ; Engel KR; Kuhlencord A; Sindermann H; Sundar S; Zappel H
Wien Klin Wochenschr; 2004; 116 Suppl 4():24-9. PubMed ID: 15683039
[TBL] [Abstract][Full Text] [Related]
20. Miltefosine (Impavido): the first oral treatment against leishmaniasis.
Sindermann H; Croft SL; Engel KR; Bommer W; Eibl HJ; Unger C; Engel J
Med Microbiol Immunol; 2004 Nov; 193(4):173-80. PubMed ID: 14513375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
